RxDoctor Payments Data

Brandi Gilmore

Child & Adolescent Psychiatry · Raceland, LANPI 1164627824

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 183 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 19 manufacturers, the largest accounting for just 23.2% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2022 at $760 and has fallen 53.0% since, to $357 in 2025.

$3,468in general payments, 2019–2025

Across 183 payments — averaging $18.95 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Merck$804
  • AbbVie$615
  • Johnson & Johnson$479
  • Takeda Pharmaceuticals U.S.A., Inc.$309
  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$208
  • Viiv Healthcare Company$179
  • plus $874 from 13 others

What the payments were for

  • Food & beverage$3,468100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$3,468 in reported general payments places this provider in the 85th percentile of 70 child & adolescent psychiatry providers in Louisiana.

See all child & adolescent psychiatry providers in Louisiana

Most prescribed under Part D

DrugClaimsCost to plans & patients
TrintellixVortioxetine Hydrobromide23$11,778
Lurasidone Hcl18$8,617
Paliperidone ErPaliperidone14$7,077
BelsomraSuvorexant16$5,988
Oxcarbazepine25$1,057
Desvenlafaxine Succinate ErDesvenlafaxine Succinate18$776
Duloxetine Hcl40$645
Quetiapine Fumarate29$570
Zolpidem Tartrate83$558
Hydroxyzine Hcl33$497
Amitriptyline Hcl28$494
Mirtazapine49$480
Hydroxyzine Pamoate12$323
Buspirone Hcl17$291
Alprazolam71$243

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Takeda Pharmaceuticals U.S.A., Inc.Trintellix$309$11,77823 claims
MerckBelsomra$804$5,98816 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 70 child & adolescent psychiatry providers in Louisiana.

Other child & adolescent psychiatry in Raceland

See the full list for Louisiana

Where these figures come from

Is this you, or does something look wrong? →